Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.
Cyrille Touzeau
No relevant relationships to disclose
Brigitte Kolb
No relevant relationships to disclose
Cyrille Hulin
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Denis Caillot
No relevant relationships to disclose
Lotfi Benboubker
No relevant relationships to disclose
Mourad Tiab
No relevant relationships to disclose
Xavier Leleu
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Murielle Roussel
Honoraria - Celgene; Janssen
Carine Chaleteix
No relevant relationships to disclose
Michel Attal
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen-Ortho
Thierry Facon
Consultant or Advisory Role - Celgene; Janssen; Millennium; Onyx
Honoraria - Celgene; Janssen
Philippe Moreau
Consultant or Advisory Role - Celgene; Janssen; Millennium; Onyx
Honoraria - Celgene; Janssen